Apr 9 |
Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024
|
Apr 8 |
Notable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay at AACR 2024 Expands the Potential of the Platform
|
Mar 5 |
Notable Labs to Present Two Posters at AACR 2024 on PPMP Platform
|
Dec 13 |
Notable Labs Donates $60,000 to MDS Foundation to Accelerate Progress for Patients with Myelodysplastic Syndromes
|
Dec 11 |
Notable Labs Funds Myelodysplastic Syndromes Foundation with $60,000 Grant
|
Dec 4 |
Notable Labs to Participate in JMP Securities Hematology and Oncology Summit
|
Nov 14 |
Notable Labs Announces Filing of Form 10-Q for Third Quarter 2023
|
Nov 9 |
Notable Labs Announces JCO Precision Oncology Publication Demonstrating PPMP Potential to Identify Novel Drug Combinations in JMML
|